Member Info for Moneymunch

More cash in the bank!!! Gla :-)

Subscription monies of £309,375 have been received by the Company in respect of this exercise.

Eric's interview , compelling and very exciting for Genflow’s transition from small cap to mid cap. Gla holders , multiple potential positive newsflow fast approaching!!! ;-)

Genflow Biosciences CEO on Acuitas collaboration: non-dilutive growth catalyst | LSE:GENF, OTCQB:GENFF https://share.google/wJZYaxH64vQv0yOVg

The following was published by Acuitas last year, and so obviously their R&D is well advanced in this area, and perhaps no surprise they're happy to collaborate with Genflow, covering all costs and R &D expenditure, to progress from the mouse model with Genflow's Sirt6,

compelling and potential panacea payload...Gla holders...a Major re-rate beckons!!!! :-)

July 3rd, 2025

Acuitas Therapeutics Collaborates on mRNA-LNP Prime

Editing Study for Genetic Liver Disease

Vancouver, B.C. – Acuitas Therapeutics today announced its collaboration on a landmark study published in Nature Biomedical Engineering, titled “Treatment of a metabolic liver disease in mice with a transient prime editing approach,” which highlights the therapeutic potential of

lipid nanoparticle (LNP)-mediated mRNA delivery for prime editing in vivo. The study – co-authored by Acuitas scientists Ying Tam, Jennifer Moon, Paulo Lin, and Steven Fan, along with partners from the University of Zurich, ETH Zurich, and the University of Pennsylvania –presents a novel approach to correct a disease-causing mutation in a mouse model of phenylketonuria (PKU), an inherited metabolic liver disorder.

The research team used two distinct strategies for liver-targeted prime editing, both of which delivered the prime editor (PE) as nucleoside-modified mRNA encapsulated in Acuitas’ LNP.

In the first strategy, the guide RNA (pegRNA) was stably expressed from an adeno-associated virus while in the second, the pegRNA was delivered as synthetic RNAs using LNP delivery.

Using these approaches, they achieved up to 47.4% editing at the Dnmt1 locus and up to 20.7% correction of the pathogenic Pahenu2 mutation in PKU mice with the enhanced PE7 variant –successfully reducing blood phenylalanine concentrations below the therapeutic threshold of 360 µmol/L.

The transient nature of mRNA-LNP delivery allowed for high editing efficiency, while minimizing prolonged editor expression and the resultant potential off-target effects, which are concerns with viral delivery systems. These findings highlight the promise of non-viral, mRNA-LNP-based prime editing as a scalable and clinically relevant platform for treating monogenic liver diseases.

And Genflow's Sirt6 Gene Therapy for Glaucoma could be hot hot hot, in the coming months. Gla ;-)

Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect

May 6, 2026

Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront. The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pair of phase 2 trials last year.

San Francisco-based Perfuse is focused on PER-001, an intravitreal implant that delivers an endothelin antagonist to the eye. Endothelin-1, a vasoconstrictor, is upregulated in glaucoma, diabetic retinopathy and age-related macular degeneration. By blocking endothelin signaling, PER-001 could improve blood flow and prevent cell death in the retinas of patients with the eye diseases.

Bayer has identified the drug candidate as a good fit for its capabilities.

Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect https://share.google/8B8Z26WHgCLsYjeGu

Great find pickedpeck, Genflow's cutting edge Sirt6 Gene Therapy combined with Acuitas's cutting edge delivery system must be on the radar of just about every Major, and only a matter of time before they show their hand. Exciting times!!! Gl :')

Ps Genflow must be of great interest to Madrigal, who continue on their buying spree in the MASH space.

Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

May 5, 2026

Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal https://share.google/mHgrtlAJH8LIjfeEF

All bodes well Porter, multiple potential material newsflow fast approaching, to take the sp to new highs, Genflow are on the brink of transition from small cap to mid cap and more. Gl....Onwards and UP!!! :-)

As of early 2026, Genflow Biosciences has a strong and growing likelihood of securing commercial deals with major pharmaceutical and animal health companies. This confidence is driven by the company’s focus on high-value data, strategic collaborations, and a maturing intellectual property (IP) position.

Key Factors Driving Commercial Deals in 2026:

Active Engagement with Industry Giants: Genflow is actively in discussions with Tier-1 animal health companies regarding its canine longevity program. The company reported receiving positive preliminary data in early 2026 and has expanded its confidentiality agreements with these potential partners.

Strategic Partnership with Acuitas: In April 2026, Genflow entered a collaboration with Acuitas Therapeutics to utilize their lipid nanoparticle (LNP) delivery platform. This is seen as a significant validation, as Acuitas is a leader in LNP technology and is committing its own resources to the partnership, which is fully funded and non-dilutive to Genflow shareholders.

Key Data Readouts in 2026: The completion of the dog aging study, with results expected in June/July 2026, is a critical milestone aimed at triggering a major licensing deal.

Targeting High-Value Areas: Genflow is concentrating on high-interest areas, including MASH (Metabolic Dysfunction-Associated Steatohepatitis) for humans and longevity/healthy aging in canine

CEO Strategy and Outlook:

Genflow CEO Dr. Eric Leire has stressed that the company's goal for 2026 is to secure non-dilutive funding through partnerships, avoiding the need to rely heavily on financing that would dilute existing shareholders. The firm has secured a 4-million-euro grant to support its MASH program, enhancing its negotiating position. The company is actively pursuing early-stage out-licensing deals, particularly for the dog program.

Risks and Considerations:

While the outlook is positive, securing a deal depends on the final data from the dog trials confirming earlier findings, and the company must still navigate the competitive landscape of the biotech sector.

In summary, given the positive preliminary data and the strengthening of their partnership network, the chances of a transformative deal for Genflow are considered to be high.

Ps Marty, Genflow aren't listed on AIM, they're listed on the LSE Main Market. Gl :-)

More than conceivable Invwell, although that would be commensurate to a market cap of £535m, which would be more than achievable on a Major deal or two for Genflow’s Sirt6 Gene Therapy Platform programs, along with a Nasdaq listing, which appears very likely as Proof of Concept is confirmed in Dog, Glaucoma and Mash in the coming weeks and months. There’s plenty of examples of Billion dollar M&A deals and similar Biotechs listed on Nasdaq are valued at many hundreds of millions if not billions, and so the potential upside could be off the scale for those invested at this time. In the meantime a re-rate to double figures and more could be very close, as we eagerly await further pivotal data from the Dog Study, and with multiple Tier 1 Animal Healthcare companies in the frame, a Major lucrative commercial licensing deal, could propel Genflow from small cap to mid cap in a blink. A very exciting period ahead for all concerned. Gl ;-)

Due diligence in progress on multiple fronts by Major Pharma!!! Gla holders....Excitement is definitely building!!! :-)))

Genflow Biosciences (LON:GENF) is a UK-based biotechnology company focusing on healthy aging and longevity by developing gene therapies that target the aging process. The company is actively moving into in vivo cell engineering and mRNA technologies to deliver its therapeutic payloads, most notably a centenarian variant of the SIRT6 gene.

Key Strategic Focus: In Vivo Engineering & mRNA

Genflow is transitioning from traditional gene therapy toward more advanced in vivo methods to treat age-related diseases.

SIRT6 Therapeutic: The lead compound, GF-1002, aims to deliver a "centenarian" variant of the SIRT6 gene (associated with exceptional longevity) to improve DNA repair and halt or reverse the aging process.

mRNA Technology Adoption: Genflow is integrating mRNA technology to introduce genetic instructions directly into cells for the production of longevity-associated proteins.

LNP Delivery Partnership: In April 2026, Genflow partnered with Acuitas Therapeutics to utilize their proprietary lipid nanoparticle (LNP) delivery platform. This partnership aims to encapsulate Genflow's SIRT6 mRNA payload for in vivo delivery, ensuring the mRNA is protected from degradation and efficiently taken up by target cells.

Non-Dilutive Development: This LNP-mRNA collaboration is fully funded by Acuitas, representing significant validation of Genflow’s approach to in vivo, non-viral gene delivery.

In Vivo Approach Advantages

Genflow's strategy leverages the benefits of in vivo cell engineering over traditional ex vivo methods:

Scalability: In vivo, mRNA-based approaches allow for broader, more scalable production than labor-intensive ex vivo therapies, making them ideal for treating large, aging populations.

Safety & Transient Expression: The use of mRNA provides transient expression (temporary protein production) rather than permanent gene modification, reducing the risk of insertional mutagenesis.

Reduced Immunogenicity: mRNA-based therapies are designed to minimize immune responses against the therapy itself.

Target Applications

Aging & Longevity: The core focus is slowing or reversing age-related decline in human tissues.

Metabolic Diseases: Genflow is investigating GF-1002 for treating MASH (Metabolic Dysfunction Associated Steatohepatitis), a chronic liver disease.

Canine Aging: The company began a clinical trial in March 2025 focusing on longevity in dogs.

By leveraging LNP-mediated in vivo mRNA delivery, Genflow aims to overcome manufacturing challenges associated with conventional gene therapies while developing potent anti-aging treatments.

Major pharmaceutical companies are aggressively investing in and acquiring gene therapy platforms to secure "blockbuster platforms" rather than just single drug assets, focusing on in vivo editing, advanced viral vectors, and next-generation delivery mechanisms. In 2025 and early 2026, this manifested in significant M&A activity focused on in vivo cell engineering and mRNA technologies.

Exactly Marty, the smart Money was accumulating cheap shares from those who were selling their's, openly excited in making a profit and predicting a fall back to sub 1p and even lower at that time. Gl, a Major re-rate beckons!!! Hold on tight for some transformational UPside !!! ;-)

With the after hours UT trade discarded ( as usual) we've opened up at 2.85p, yesterday's closing price before the UT trade. Gl ;-)

Yep, the after hours UT sell trade, probably means we'll open up tomorrow at 8am regardless of any news, in the same way the sp opens down the following day, when an after hours UT buy trade sends the sp up at close. Not to sure why they bother, but all smoke and mirrors springs to mind. Gl ;-)

Nice one pickedpeck, a great summary on proceedings, and such an exciting time to be invested with so many potential game changing catalysts in the pipeline, and now looks forward to a continued run of positive material news to take the sp to new highs and beyond. The granting of the Key Patent is extremely close according to Eric, it entered National Phase in Europe last year, and so initial approval and granting presumably covers Europe and maybe other geographical areas, but according to the EPO Global Dossier, it's also been accepted by UPTSO for National Phase in the US, which is highly significant and Company defining, and no doubt will be very well received by the market when confirmed. Gl ;-)

Forward look

Looking ahead, Genflow enters the next phase of development with a strengthened platform, a diversified and advancing pipeline, and enhanced delivery and intellectual property capabilities.

Our key priorities include completing the ongoing canine clinical trial and leveraging the resulting translational data, advancing the glaucoma programme with IRIS Pharma towards preclinical proof-of-concept, progressing the sarcopenia programme towards clinical readiness, and expanding our LNP/mRNA collaboration framework.

By combining scientific excellence with disciplined capital allocation, we believe Genflow is well positioned to deliver sustainable value for all stakeholders.

On behalf of the Board, I would like to thank our shareholders, partners, and employees for their continued support as we work to translate SIRT6 science into therapies that improve lives.

Human Health Pipeline

Our human health pipeline spans metabolic dysfunction-associated steatohepatitis (MASH), sarcopenia, Werner syndrome, and ophthalmology. During the period, we made notable progress across several of these programmes.

In ophthalmology, we formally initiated our glaucoma programme in collaboration with IRIS Pharma, a leading contract research organisation specialising in ocular pharmacology. This partnership represents an important step in translating our preclinical SIRT6 findings into a structured drug development programme focused on optic nerve neuroprotection. While current glaucoma treatments primarily target intraocular pressure, they do not prevent retinal ganglion cell loss. Our approach, supported by preclinical evidence of SIRT6-mediated neuroprotection, has the potential to deliver disease-modifying benefits in a global market valued at approximately USD 9 billion.

In sarcopenia, we have continued to advance the programme aimed at combating age-related muscle loss, leveraging translational data generated from our canine studies to strengthen the foundation for future clinical development. This remains a strategically important programme given the significant unmet medical need and the absence of approved pharmacological therapies.

Delivery Technology: Transition to LNP/mRNA Platforms

A key strategic milestone during the year was the transition from AAV-based delivery systems to LNP/mRNA technologies, enabled through collaborations with leading LNP technology partners.

This shift represents a meaningful advancement in our delivery approach. LNP/mRNA platforms offer enhanced manufacturability, a well-established safety profile supported by approved vaccines and therapeutics, and the potential for repeat dosing-an important advantage in the treatment of chronic, age-related conditions. These collaborations position Genflow to access best-in-class delivery solutions and accelerate clinical translation across our pipeline.

Intellectual Property: Advancement to National Phase

We have made significant progress in advancing our core patent portfolio into the national phase across multiple jurisdictions. This milestone strengthens our global intellectual property position and underpins the long-term commercial value of the Genflow platform. Expanding patent protection in key territories enhances our freedom to operate and ensures robust protection of our proprietary SIRT6 centenarian innovations as we advance towards clinical-stage development.

Chairperson's Report

Dear Shareholders,

Introduction

I am pleased to present an update to shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on our performance for 2025.

As at 31 December 2025, Genflow has delivered a period of significant operational and strategic progress across both its Human Health and Animal Health divisions, advancing our mission to extend health span through our proprietary SIRT6 centenarian-based gene therapy platform. The period has been characterised by meaningful clinical, scientific, financial, and intellectual property achievements, reinforcing our confidence in the strength of our platform and our commitment to delivering long-term shareholder value.

Animal Health: Canine Clinical Trial Progressing as Planned

Our ongoing SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial targeting health span and sarcopenia, conducted in partnership with Syngene, continues to progress according to plan. This randomized, blinded, controlled study includes 28 beagle dogs aged 10 years and older, with treatment cohorts having receiving three different modalities of SIRT6 gene therapy. We are encouraged by interim clinical data from the study, received in early 2026, with all dogs continuing to be monitored and evaluated and completion expected by the end of July 2026.

These early findings support the biological rationale for SIRT6-based interventions in ageing canine populations and provide valuable translational insights for our broader human health pipeline, particularly in sarcopenia. In parallel, we have initiated preliminary partnering discussions with leading animal health companies, reflecting growing industry interest in this programme and its commercial potential.

Bye bye sub 3p!!! :-)))